JPRN-jRCT2080220205未知3 期
Safety comformation study of R435 (Bevacizumab) in patients with metastatic colorectal cancer
适应症
试验速览
- 阶段
- 3 期
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 <= 74age old（—）
- 性别
- All
入选标准
- •PS=0-1, Age < 75 yrs
排除标准
- 未提供
研究者
相似试验
未知
3 期
A study of R435 (Bevacizumab) in Combination With R340 (Capecitabine) and Cisplatin in Patients With Advanced Gastric Cancer.Gastric CancerJPRN-jRCT2080220416Chugai Pharmaceutical Co., Ltd.
未知
3 期
A compassionate use study of R435(Bevacizumab) in chemotherapy naive and inoperable malignant pleural mesothelioma patientschemotherapy naive and inoperable malignant pleural mesotheliomaJPRN-jRCT2080223406CHUGAI PHARMACEUTICAL CO., LTD.12
未知
1 期
Phase I/II study of R435 (Bevacizumab) in patients with metastatic colorectal cancerMetastatic colorectal cancerJPRN-jRCT2080220022Chugai Pharmaceutical Co., Ltd.
未知
2 期
Phase II clinical study of R435 (bevacizumab) in combination with paclitaxel in patients with inoperable metastatic breast cancerInoperable metastatic breast cancerJPRN-jRCT2080220385Chugai Pharmaceutical Co., Ltd.
已完成
不适用
Safety assessment of treatment with bevacizumab in metastatic colorectal cancerMetastatic colorectal cancerMalignant neoplasm of rectosigmoid junctionCancerISRCTN36011949Institute of Oncology Ljubljana (Slovenia)250